NCT03754790
Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX
Campos del registro
- Estado general
- COMPLETED
- Condiciones
- Hemophilia
- Tipo de estudio
- INTERVENTIONAL
- Fase
- PHASE3
- Objetivo principal
- TREATMENT
- Tipo de intervención
- DRUG
- Intervenciones
- Fitusiran
- Patrocinador principal
- Genzyme, a Sanofi Company (INDUSTRY)
En caché: 2026-10-01 04:05:12
Resumen breve
Primary Objective:
To characterize the long-term safety and tolerability of fitusiran
Secondary Objectives:
* To characterize the efficacy and long-term efficacy of fitusiran as assessed by the frequency of:
* Bleeding episodes
* Spontaneous bleeding episodes
* Joint bleeding episodes
* To characterize the effects of fitusiran on health-related quality of life (HRQOL) measures in participants ≥17 years of age
To characterize the long-term safety and tolerability of fitusiran
Secondary Objectives:
* To characterize the efficacy and long-term efficacy of fitusiran as assessed by the frequency of:
* Bleeding episodes
* Spontaneous bleeding episodes
* Joint bleeding episodes
* To characterize the effects of fitusiran on health-related quality of life (HRQOL) measures in participants ≥17 years of age
Contacto
¿Necesita un informe o redacción médica basada en este ensayo?
Iniciar sesión con Kakao para continuar